|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACSL6 |
Gene summary for ACSL6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACSL6 | Gene ID | 23305 |
| Gene name | acyl-CoA synthetase long chain family member 6 | |
| Gene Alias | ACS2 | |
| Cytomap | 5q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0000038 | UniProtAcc | Q9UKU0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23305 | ACSL6 | HCC1 | Human | Liver | HCC | 8.93e-06 | 1.44e+00 | 0.5336 |
| 23305 | ACSL6 | HCC2 | Human | Liver | HCC | 4.79e-08 | 1.38e+00 | 0.5341 |
| 23305 | ACSL6 | HCC5 | Human | Liver | HCC | 8.62e-07 | 6.44e-01 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
| GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
| GO:001969322 | Liver | HCC | ribose phosphate metabolic process | 248/7958 | 396/18723 | 3.15e-16 | 2.70e-14 | 248 |
| GO:000925922 | Liver | HCC | ribonucleotide metabolic process | 240/7958 | 385/18723 | 2.07e-15 | 1.51e-13 | 240 |
| GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
| GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
| GO:000915022 | Liver | HCC | purine ribonucleotide metabolic process | 226/7958 | 368/18723 | 1.36e-13 | 7.69e-12 | 226 |
| GO:007252122 | Liver | HCC | purine-containing compound metabolic process | 250/7958 | 416/18723 | 2.26e-13 | 1.24e-11 | 250 |
| GO:000616322 | Liver | HCC | purine nucleotide metabolic process | 236/7958 | 396/18723 | 3.59e-12 | 1.62e-10 | 236 |
| GO:00338652 | Liver | HCC | nucleoside bisphosphate metabolic process | 88/7958 | 128/18723 | 1.63e-09 | 4.78e-08 | 88 |
| GO:00338752 | Liver | HCC | ribonucleoside bisphosphate metabolic process | 88/7958 | 128/18723 | 1.63e-09 | 4.78e-08 | 88 |
| GO:00340322 | Liver | HCC | purine nucleoside bisphosphate metabolic process | 88/7958 | 128/18723 | 1.63e-09 | 4.78e-08 | 88 |
| GO:00066372 | Liver | HCC | acyl-CoA metabolic process | 67/7958 | 96/18723 | 5.62e-08 | 1.19e-06 | 67 |
| GO:00353832 | Liver | HCC | thioester metabolic process | 67/7958 | 96/18723 | 5.62e-08 | 1.19e-06 | 67 |
| GO:000916512 | Liver | HCC | nucleotide biosynthetic process | 150/7958 | 254/18723 | 6.79e-08 | 1.40e-06 | 150 |
| GO:190129312 | Liver | HCC | nucleoside phosphate biosynthetic process | 151/7958 | 256/18723 | 6.84e-08 | 1.41e-06 | 151 |
| GO:00442722 | Liver | HCC | sulfur compound biosynthetic process | 95/7958 | 148/18723 | 7.89e-08 | 1.58e-06 | 95 |
| GO:004639012 | Liver | HCC | ribose phosphate biosynthetic process | 116/7958 | 190/18723 | 1.79e-07 | 3.29e-06 | 116 |
| GO:000926012 | Liver | HCC | ribonucleotide biosynthetic process | 111/7958 | 182/18723 | 3.53e-07 | 6.03e-06 | 111 |
| GO:000915212 | Liver | HCC | purine ribonucleotide biosynthetic process | 101/7958 | 169/18723 | 4.30e-06 | 5.50e-05 | 101 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0471422 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
| hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
| hsa041464 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| hsa049202 | Liver | HCC | Adipocytokine signaling pathway | 45/4020 | 69/8465 | 2.19e-03 | 7.55e-03 | 4.20e-03 | 45 |
| hsa033204 | Liver | HCC | PPAR signaling pathway | 48/4020 | 75/8465 | 2.83e-03 | 9.37e-03 | 5.21e-03 | 48 |
| hsa00061 | Liver | HCC | Fatty acid biosynthesis | 14/4020 | 18/8465 | 8.82e-03 | 2.36e-02 | 1.32e-02 | 14 |
| hsa0471432 | Liver | HCC | Thermogenesis | 170/4020 | 232/8465 | 5.36e-16 | 2.25e-14 | 1.25e-14 | 170 |
| hsa012125 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
| hsa041465 | Liver | HCC | Peroxisome | 58/4020 | 82/8465 | 1.57e-05 | 1.05e-04 | 5.85e-05 | 58 |
| hsa049203 | Liver | HCC | Adipocytokine signaling pathway | 45/4020 | 69/8465 | 2.19e-03 | 7.55e-03 | 4.20e-03 | 45 |
| hsa033205 | Liver | HCC | PPAR signaling pathway | 48/4020 | 75/8465 | 2.83e-03 | 9.37e-03 | 5.21e-03 | 48 |
| hsa000611 | Liver | HCC | Fatty acid biosynthesis | 14/4020 | 18/8465 | 8.82e-03 | 2.36e-02 | 1.32e-02 | 14 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACSL6 | SNV | Missense_Mutation | c.481N>A | p.Gly161Arg | p.G161R | Q9UKU0 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-A8-A08P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| ACSL6 | SNV | Missense_Mutation | novel | c.766N>A | p.Glu256Lys | p.E256K | Q9UKU0 | protein_coding | tolerated(0.13) | benign(0.01) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACSL6 | SNV | Missense_Mutation | c.1235N>A | p.Arg412His | p.R412H | Q9UKU0 | protein_coding | deleterious(0.01) | benign(0.039) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| ACSL6 | SNV | Missense_Mutation | c.1676N>A | p.Gly559Asp | p.G559D | Q9UKU0 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| ACSL6 | SNV | Missense_Mutation | novel | c.1971N>T | p.Lys657Asn | p.K657N | Q9UKU0 | protein_coding | tolerated(0.09) | benign(0.02) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD |
| ACSL6 | insertion | Nonsense_Mutation | novel | c.1089_1090insTTGAGCTGCAGAGCTGATTGTGTTTATCATTAGGAAG | p.Gly364LeufsTer11 | p.G364Lfs*11 | Q9UKU0 | protein_coding | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | ||
| ACSL6 | SNV | Missense_Mutation | c.313N>G | p.Gln105Glu | p.Q105E | Q9UKU0 | protein_coding | tolerated(0.94) | benign(0) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ACSL6 | SNV | Missense_Mutation | rs368021532 | c.826G>A | p.Val276Met | p.V276M | Q9UKU0 | protein_coding | tolerated(0.22) | benign(0.03) | TCGA-FU-A5XV-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| ACSL6 | SNV | Missense_Mutation | novel | c.1525N>A | p.Leu509Ile | p.L509I | Q9UKU0 | protein_coding | tolerated(0.25) | benign(0.03) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| ACSL6 | SNV | Missense_Mutation | c.503A>T | p.Lys168Ile | p.K168I | Q9UKU0 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-AA-3530-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |